These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Chitosan-dibenzylideneacetone based Schiff base: Evaluation of antimicrobial activity and in-vitro cytotoxicity on MCF-7 and L-132.
    Author: Limbachiya P, Patel V, Rami G, Vora J.
    Journal: Int J Biol Macromol; 2023 Oct 01; 250():126268. PubMed ID: 37567544.
    Abstract:
    This study holds significant importance as it explores the synthesis and characterization of two chitosan dibenzylideneacetone Schiff bases. Various analytical techniques, such as UV-visible spectroscopy, FTIR, XRD, TGA, DSC, SEM, and elemental analysis, were employed to thoroughly examine these derivatives. The antimicrobial activity of the chitosan derivatives was evaluated against a range of bacterial and fungal strains, while cytotoxicity tests were conducted on MCF-7, L-132, and VERO cell lines. In the antimicrobial tests, the chitosan derivatives exhibited remarkable antibacterial properties against S. aureus, E. coli, and Pseudomonas aeruginosa, as well as potent antifungal properties against Candida albicans and Aspergillus fumigatus. The cytotoxicity assessment revealed that the dibenzylideneacetone chitosan Schiff base (CHDBA) showed significant effectiveness against the L-132 cell line, surpassing the efficacy of doxorubicin by 2.44 times. Moreover, it exhibited substantial activity against the L-132 and MCF-7 cell lines, with IC50 values of 55.29 μg/mL and 185.8 μg/mL, respectively. Notably, none of the chitosan derivatives demonstrated cytotoxicity towards the normal cell line, indicating their non-toxic nature and safe usability. Based on these findings, it is evident that CHDBA holds promise for further development as a potential treatment option for breast cancer and lung cancer.
    [Abstract] [Full Text] [Related] [New Search]